Axsome Therapeutics, Inc. (LON:0HKF)
London flag London · Delayed Price · Currency is GBP · Price in USD
104.17
-0.74 (-0.71%)
At close: Jul 2, 2025

Axsome Therapeutics Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation.

Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.
Country United States
Founded 2012
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 683
CEO Herriot Tabuteau

Contact Details

Address:
One World Trade Center
New York, Delaware 10007
United States
Phone 212 332 3241
Website axsome.com

Stock Details

Ticker Symbol 0HKF
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US05464T1043
SIC Code 2836

Key Executives

Name Position
Herriot Tabuteau Chief Executive Officer
Nick Pizzie Chief Financial Officer
Mark Jacobson Chief Operating Officer